Journal Watch · ACS Nano · 2026
Dynamic Simulation Assists Insights into the Deafness Prevention of a Self-Assembly Pd Nanozyme with Intrinsic Targeting.
This study not only reveals that lysosomal damage-iron metabolism dysregulation-oxidative stress is a key axis driving aminoglycoside ototoxicity, but also establishes Pd SAN whose structure can be accurately deciphered with mass spectroscopy as an innovatively designed cochlea-targeting antioxidant nanomaterial with strong potential for clinical translation in deafness prevention.
TL;DR
This study not only reveals that lysosomal damage-iron metabolism dysregulation-oxidative stress is a key axis driving aminoglycoside ototoxicity, but also establishes Pd SAN whose structure can be accurately deciphered with mass spectroscopy as an innovatively designed cochlea-targeting antioxidant nanomaterial with strong potential for clinical translation in deafness prevention.
Key findings
- Notably, dynamic simulation demonstrates that Pd SAN shows comparable binding affinity to critical HC proteins (Prestin, Myo7a) as superoxide dismutase (SOD), and functionally suppresses neomycin-induced ferroptosis with equal or greater efficacy.
- In vivo experiments confirm that Pd SAN prevents auditory threshold shifts and mitigates cochlear structural injury, underscoring its translational potential.
- This study not only reveals that lysosomal damage-iron metabolism dysregulation-oxidative stress is a key axis driving aminoglycoside ototoxicity, but also establishes Pd SAN whose structure can be accurately deciphered with mass spectroscopy as an innovatively designed cochlea-targeting antioxidant nanomaterial with strong potential for clinical translation in deafness prevention.
What they did
With identical Pd<sub>1</sub>-O<sub>4</sub> coordinating sites and controllable size, Pd SAN effectively penetrates the BLB, accumulates within the cochlea, and protects HCs from neomycin-induced damage. Mechanistically, Pd SAN inhibits ferroptosis by preserving glutathione redox balance, reducing lipid peroxidation, stabilizing lysosomal membranes, and maintaining Fe<sup>2+</sup> homeostasis.
Full abstract (original)
Background: With aging increases the possibility of body impairment, deafness prevention remains a major unmet clinical challenge, largely due to the lack of effective therapeutics capable of targeting cochlear hair cells (HCs) across the blood-labyrinth barrier (BLB). Here, we report a precisely structured palladium-polyoxometalate coordinated antioxidant nanoagent (Pd single-atom nanozyme, Pd SAN), which demonstrates superior antioxidative enzyme-like capacity and robust biosafety.
What they did: With identical Pd<sub>1</sub>-O<sub>4</sub> coordinating sites and controllable size, Pd SAN effectively penetrates the BLB, accumulates within the cochlea, and protects HCs from neomycin-induced damage. Mechanistically, Pd SAN inhibits ferroptosis by preserving glutathione redox balance, reducing lipid peroxidation, stabilizing lysosomal membranes, and maintaining Fe<sup>2+</sup> homeostasis.
Results & conclusions: Notably, dynamic simulation demonstrates that Pd SAN shows comparable binding affinity to critical HC proteins (Prestin, Myo7a) as superoxide dismutase (SOD), and functionally suppresses neomycin-induced ferroptosis with equal or greater efficacy. In vivo experiments confirm that Pd SAN prevents auditory threshold shifts and mitigates cochlear structural injury, underscoring its translational potential. This study not only reveals that lysosomal damage-iron metabolism dysregulation-oxidative stress is a key axis driving aminoglycoside ototoxicity, but also establishes Pd SAN whose structure can be accurately deciphered with mass spectroscopy as an innovatively designed cochlea-targeting antioxidant nanomaterial with strong potential for clinical translation in deafness prevention.
Abstract © the authors / ACS Nano (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acsnano.5c19608 · PubMed 41656738.
Why it matters for pharma & biotech
- Relevant to Biotechnology & Methods teams tracking ACS Nano for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this ACS Nano study find?
This study not only reveals that lysosomal damage-iron metabolism dysregulation-oxidative stress is a key axis driving aminoglycoside ototoxicity, but also establishes Pd SAN whose structure can be accurately deciphered with mass spectroscopy as an innovatively designed cochlea-targeting antioxidant nanomaterial with strong potential for clinical translation in deafness prevention.
What type of study is this?
It is a research study, published in ACS Nano in 2026. With identical Pd<sub>1</sub>-O<sub>4</sub> coordinating sites and controllable size, Pd SAN effectively penetrates the BLB, accumulates within the cochlea, and protects HCs from neomycin-induced damage.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acsnano.5c19608. PubMed ID: 41656738. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/dynamic-simulation-assists-insights-into-the-deafness-prevention-of-a-se-c19608/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides